Pomegranate products for prostate-cancer progression

Evidence label: No demonstrated cancer-control benefit · Clinical goal: slow prostate-specific antigen rise or disease progression

Evidence at a glance

Population: men with a rising PSA after local therapy or localized prostate cancer on active surveillance.
Intervention: pomegranate juice or standardized extract taken daily.
Result: randomized placebo-controlled studies did not show a significant benefit in PSA doubling time, biopsy findings or other progression measures.

What was studied

A placebo-controlled trial enrolled 183 eligible men with rising PSA after surgery or radiotherapy. Participants were randomized 2:1; 102 received extract, 64 placebo and 17 juice under an earlier protocol.

A separate placebo-controlled study randomized 30 men on active surveillance to 1,000 mg/day of pomegranate extract or placebo for 12 months.

What the evidence shows

In the larger trial, PSA doubling time lengthened in all groups, but the change did not differ significantly between pomegranate and placebo (P>.05).

In the active-surveillance trial, pomegranate did not improve PSA kinetics or biopsy measures compared with placebo.

An earlier single-arm juice study reported longer PSA doubling time, but without a randomized control it could not separate treatment effect from natural fluctuation or regression to the mean. The later controlled trials did not confirm a benefit.

Limits and uncertainty

Sample sizes were modest and formulations varied. PSA kinetics are not the same as metastasis-free or overall survival.

These results do not test pomegranate as food in an ordinary diet; they test particular juice or extract regimens for cancer control.

Safety and practical context

Pomegranate food products can add sugar or calories; concentrated products vary in composition. Discuss extracts with the oncology pharmacist because supplement labeling, contamination and medication interactions may be uncertain.

Do not replace active surveillance, imaging, biopsy or recommended treatment with pomegranate products.

Questions for the care team

Am I using pomegranate as food or expecting an anticancer effect?
Could juice affect glucose control, weight goals or medicines?
Which clinical measures—not PSA alone—will guide treatment decisions?

Sources

Literature searched: October 14, 2026 · Record appraised: October 14, 2026

Educational evidence summary, not personal medical advice. Supportive approaches should complement—not replace—appropriate cancer treatment and symptom management.